MedicaSafe, Inc.
Malcolm Dell has a diverse range of work experience. Malcolm began their professional journey as an Engineering Intern at MedicaSafe, Inc. from November 2014 to April 2015. Malcolm then transitioned to the role of Product Engineer at the same company, where they worked from April 2015 to January 2019. Following this, Malcolm served as a Senior Mechanical Engineer at MedicaSafe, Inc. from January 2019 to July 2022. Currently, they hold the position of Director of Product Management and Development at the same company, a role they started in July 2022. In addition to their work at MedicaSafe, Malcolm was a Master's Student at The Cooper Union from September 2014 to May 2017.
Malcolm Dell obtained a Master's Degree in Mechanical Engineering from The Cooper Union for the Advancement of Science and Art, from 2014 to 2017. Prior to that, they also completed their Bachelor's Degree in Mechanical Engineering at the same institution, from 2010 to 2014. Additionally, Malcolm obtained a certification in Product Management Course from General Assembly in January 2020.
This person is not in any teams
This person is not in any offices
MedicaSafe, Inc.
MedicaSafe creates innovative technologies for guiding patients through high-stakes outpatient medication therapies. These solutions also address needs for regular patient assessment, tracking, and medication access management, enabling creation of comprehensive treatment management systems that reduce labor and costs while improving outcomes. Technology / Differentiation A patent-protected approach, developed with funding from the NIH, facilitates patient behavioral modification and patient tracking. The system can be geared to correct underuse of medication or, alternatively, limit drug access to prevent overuse. Market / Customers Lack of adherence/compliance in a clinical setting is estimated to produce 125,000 deaths and $100 billion in health care costs annually. MedicaSafe is targeting areas of specific applicability such as: 1) Risk Management (REMS) 2) High-Value Chronic Treatments 3) Clinical Trials